Retention in Care and Adherence to ART are Critical Elements of HIV Care Interventions

AIDS and Behavior

Volumn 18, Issue , 2014, Pages 465-475

  Stricker, Sebastian M ^a   Fox, Kathleen A ^b   Baggaley, Rachel ^b   Negussie, Eyerusalem ^b   de Pee, Saskia ^a   Grede, Nils ^a   Bloem, Martin W ^a  

^a World Food Programme   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adherence; ART; HIV AIDS; Measurement; Retention

Indexed keywords

ANTIRETROVIRUS AGENT;

DISEASE COURSE; FOLLOW UP; HIV INFECTIONS; HUMAN; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PSYCHOLOGY;

ANTI-RETROVIRAL AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84922392803     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-013-0598-6     Document Type: Article

References (94)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Together We Will End AIDS. Geneva: UNAIDS; 2012.
2. World Health Organization (WHO), United Nations Children’s Fund (UNICEF), Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV/AIDS Response: Epidemic Update and Health Sectors Progress Towards Universal Access. Progress Report 2011. Geneva: WHO; 2011.
3. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;25(5):331–42.
4. Haynes RB, McDonald H, Garg AX. Montegue P. Cochrane Database Syst Rev: Interventions for helping patients to follow prescriptions for medications; 2002 (2):CD000011. [NOTE: updated 2005;(4):CD000011.].
5. DeMaria AN. Adherence, compliance, concordance, or the lack thereof. J Am Coll Cardiol. 2012;59(12):1120–1.
6. Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol. 2007;63(4):383–4.
7. Bell SJ, Airaksinen MS, Lyles A, Chen TF, Aslani P. Concordance is not synonymous with compliance or adherence. Br J Clin Pharmacol. 2007;64(5):710–1.
8. Steiner EM, Earnest MA. The language of medication-taking. Ann Intern Med. 2000;132:926–30.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
10. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.
11. Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med. 2004;58(4):851–62.
12. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.
13. Lamb MR, El-Sadr WM, Geng E, Nash D. Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa. PLoS One. 2012;7(6):e38443.
14. Chi BH, Cantrell RA, Mwango A, et al. An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol. 2010;171(8):924–31.
15. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8(10):e1001111.
16. Fairman K, Motheral B. Evaluating medication adherence: which measure is right for your program? J Manage Care Pharm. 2000;6:499–504.
17. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.
18. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials. 2000;1(1):36–46.
19. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.
20. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–71.
21. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS. 1999;13(3):185–97.
22. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124–31.
23. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.
24. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003;6(5):566–73.
25. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.
26. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–96.
27. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.
28. Coenen T, Lundgren J, Lazarus JV, Matic S. Optimal HIV testing and earlier care: the way forward in Europe. HIV Med. 2008;9(Suppl 2):1–5.
29. US Centers for Disease Control and Prevention (CDC). HIV surveillance—United States, 1981–2008. Morb Mortal Wkly Rep. 2011;60(21):689–93.
30. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr. 2007;46(Suppl 1):S3–8.
31. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056.
32. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
33. Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24(17):2717–25.
34. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43(6):770–6.
35. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health. 2009;14(9):1048–58.
36. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1–15.
37. Urquhart J. Defining the margins for errors in patient compliance with prescribed drug regimens. Pharmacoepidemiol Drug Saf. 2000;9(7):565–8.
38. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci. 1998;20(2):73–7.
39. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.
40. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000;21(Suppl 5):S188–94.
41. Nunnally JC, Berstein I. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
42. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52(4):493–506.
43. Chalker JC, Andualem T, Gitau LN, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. BMC Health Serv Res. 2010;19(10):43.
44. Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;19(10):42.
45. Steel G, Nwokike J, Joshi MP. Development of a Multi-Method Tool to Measure ART Adherence in Resource-Constrained Settings: The South Africa Experience. Submitted to the USAID by RPM plus. Arlington, Va: Management Sciences for Health; 2007.
46. Herbst AJ, Cooke GS, Bärnighausen T, KanyKany A, Tanser F, Newell ML. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ. 2009;87(10):754–62.
47. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.
48. Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339(6):405–6.
49. Chan KC, Wong KH, Lee SS. Universal decline in mortality in patients with advanced HIV-1 disease in various demographic subpopulations after the introduction of HAART in Hong Kong, from 1993 to 2002. HIV Med. 2006;7(3):186–92.
50. World Health Organization (WHO). WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva: WHO; 2001.
51. Phillips A, Pezzotti P. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004;18(1):51–8.
52. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18(16):2145–51.
53. Hocking JS, Rodger AJ, Rhodes DG, Crofts N. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis—characteristics of individuals. Int J STD AIDS. 2000;11(8):503–8.
54. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.
55. de Olalla PG, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105–10.
56. Hoggs RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.
57. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57(10):1107–10.
58. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
59. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84.
60. Giordano TP, Gifford AL, White AC Jr, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493–9.
61. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):696–9.
62. Green DA. There are no paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;54(3):694.
63. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.
64. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23(9):1035–46.
65. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22(1):75–82.
66. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Geneva: WHO; 2010. p. 2010.
67. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: US Department of Health and Human Services; 2012.
68. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol. 2004;30(1):1–10.
69. World Health Organization (WHO). WHO HIV Drug Resistance Report 2012. Geneva: WHO; 2012.
70. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
71. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404.
72. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.
73. Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care cost. Ann Intern Med. 2010;152(1):18–25.
74. Knobel H, Carmona A, Guelar A, Gonzolez A, Hernecki J, Diez A. Adherence in patients treated with HAART: influence in hospital admissions. Durban: International AIDS Conference; 2000 [abstract MoPeD2556].
75. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24(6):915–9.
76. World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS). The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support. Geneva: WHO; 2011.
77. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669–80.
78. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.
79. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;4(Suppl 1):S2–6.
80. Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist’s interventions. AIDS Care. 2010;22(19):1189–94.
81. Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280–9.
82. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.
83. Jani AV, Sitoe AE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572–9.
84. Joint United Nations Programme on HIV/AIDS (UNAIDS). Breaking News Supplement: Meeting the Investment Challenge. Geneva: UNAIDS; 2012.
85. Torpey K, Kabaso M, Kasonde P, et al. Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv Res. 2010;10:29.
86. Killam WP, Tambatamba BC, Chintu N, et al. Antiretroviral therapy in antenatal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evaluation. AIDS. 2010;24(1):85–91.
87. Louwagie G, Girdler-Brown B, Odendaal R, Rossouw T, Johnson S, Van der Walt M. Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care. Int J Tuberc Lung Dis. 2012;16(8):1052–8.
88. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84.
89. Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.
90. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6(1):e1000011.
91. Wouters E, Van Damme W, van Rensburg D, Meulemans H. Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa. AIDS. 2008;22(18):2545–8.
92. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr. 2011;56(2):e39–44.
93. United Nations General Assembly. Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. New York: United Nations General Assembly; 2011.
94. Joint United Nations Programme on HIV/AIDS (UNAIDS). Getting to Zero: 2011-2015 Strategy. Geneva: UNAIDS; 2010.